<SEC-DOCUMENT>0001213900-24-011360.txt : 20240208
<SEC-HEADER>0001213900-24-011360.hdr.sgml : 20240208
<ACCEPTANCE-DATETIME>20240208093048
ACCESSION NUMBER:		0001213900-24-011360
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20240208
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240208
DATE AS OF CHANGE:		20240208

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ABVC BIOPHARMA, INC.
		CENTRAL INDEX KEY:			0001173313
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				260014658
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40700
		FILM NUMBER:		24607109

	BUSINESS ADDRESS:	
		STREET 1:		44370 OLD WARM SPRINGS BLVD.
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94538
		BUSINESS PHONE:		510-668-0881

	MAIL ADDRESS:	
		STREET 1:		44370 OLD WARM SPRINGS BLVD.
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94538

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	American BriVision (Holding) Corp
		DATE OF NAME CHANGE:	20160111

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	METU BRANDS, INC.
		DATE OF NAME CHANGE:	20150908

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ECOLOGY COATINGS, INC.
		DATE OF NAME CHANGE:	20080821
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea193134-8k_abvcbio.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:ABVC="http://abvcpharma.com/20240208">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_034_ABVC_abvcpharma.com_20240208 -->
<!-- Field: Set; Name: xdx; ID: xdx_046_20240208_20240208 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DEntityCentralIndexKey_0001173313 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2024-02-08" name="dei:AmendmentFlag" id="ixv-296">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-02-08" name="dei:EntityCentralIndexKey" id="ixv-297">0001173313</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="abvc-20240208.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2024-02-08">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-08</xbrli:startDate>
        <xbrli:endDate>2024-02-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; text-align: center; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Washington, DC 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>FORM <span id="xdx_90D_edei--DocumentType_c20240208__20240208_zJfYay2TiwB"><ix:nonNumeric contextRef="AsOf2024-02-08" name="dei:DocumentType" id="ixv-317">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of Report (Date of earliest event reported):
<span id="xdx_908_edei--DocumentPeriodEndDate_c20240208__20240208_zimQYN1XVlp3"><ix:nonNumeric contextRef="AsOf2024-02-08" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="ixv-318">February 8, 2024</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span id="xdx_90C_edei--EntityRegistrantName_c20240208__20240208_zbZINJC5OYQa"><ix:nonNumeric contextRef="AsOf2024-02-08" name="dei:EntityRegistrantName" id="ixv-319">ABVC BIOPHARMA, INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_900_edei--EntityIncorporationStateCountryCode_c20240208__20240208_zhCguLafV18f"><ix:nonNumeric contextRef="AsOf2024-02-08" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="ixv-320">Nevada</ix:nonNumeric></span></b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90C_edei--EntityFileNumber_c20240208__20240208_zE2UFymPXS0l"><ix:nonNumeric contextRef="AsOf2024-02-08" name="dei:EntityFileNumber" id="ixv-321">001-40700</ix:nonNumeric></span></b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_909_edei--EntityTaxIdentificationNumber_c20240208__20240208_zlfXXMn6KPka"><ix:nonNumeric contextRef="AsOf2024-02-08" name="dei:EntityTaxIdentificationNumber" id="ixv-322">26-0014658</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction<br/>
of incorporation)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission File Number)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS Employer<br/>
Identification No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; width: 49%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_900_edei--EntityAddressAddressLine1_c20240208__20240208_zGDdHxGXcxxa"><ix:nonNumeric contextRef="AsOf2024-02-08" name="dei:EntityAddressAddressLine1" id="ixv-323">44370 Old Warm Springs Blvd.</ix:nonNumeric></span></b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90C_edei--EntityAddressCityOrTown_c20240208__20240208_zGuQ5kCz3yxf"><ix:nonNumeric contextRef="AsOf2024-02-08" name="dei:EntityAddressCityOrTown" id="ixv-324">Fremont</ix:nonNumeric></span>, <span id="xdx_902_edei--EntityAddressStateOrProvince_c20240208__20240208_z91BM1c0ty4d"><ix:nonNumeric contextRef="AsOf2024-02-08" name="dei:EntityAddressStateOrProvince" id="ixv-325">CA</ix:nonNumeric></span></b></p></td>
    <td style="vertical-align: top; width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_909_edei--EntityAddressPostalZipCode_c20240208__20240208_zUQ8eHfJL0H6"><ix:nonNumeric contextRef="AsOf2024-02-08" name="dei:EntityAddressPostalZipCode" id="ixv-326">94538</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of principal executive offices)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&#8217;s telephone number including area
code: <b>(<span id="xdx_90C_edei--CityAreaCode_c20240208__20240208_zFHZT8DEfZR9"><ix:nonNumeric contextRef="AsOf2024-02-08" name="dei:CityAreaCode" id="ixv-327">510</ix:nonNumeric></span>) <span id="xdx_901_edei--LocalPhoneNumber_c20240208__20240208_z7OmNhR3MnT4"><ix:nonNumeric contextRef="AsOf2024-02-08" name="dei:LocalPhoneNumber" id="ixv-328">668-0881</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed since
last report)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--WrittenCommunications_c20240208__20240208_zh41pYm5Xvc7"><ix:nonNumeric contextRef="AsOf2024-02-08" format="ixt:booleanfalse" name="dei:WrittenCommunications" id="ixv-329">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--SolicitingMaterial_c20240208__20240208_zh6ZtygQzyQg"><ix:nonNumeric contextRef="AsOf2024-02-08" format="ixt:booleanfalse" name="dei:SolicitingMaterial" id="ixv-330">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--PreCommencementTenderOffer_c20240208__20240208_z1jGgxM7N6Pc"><ix:nonNumeric contextRef="AsOf2024-02-08" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer" id="ixv-331">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--PreCommencementIssuerTenderOffer_c20240208__20240208_zgB3UNLUr77k"><ix:nonNumeric contextRef="AsOf2024-02-08" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer" id="ixv-332">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap; vertical-align: bottom; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title of Each Class</span></td>
    <td style="white-space: nowrap; vertical-align: top; width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap; vertical-align: bottom; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading Symbol</span></td>
    <td style="white-space: nowrap; vertical-align: top; width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap; vertical-align: bottom; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of each exchange on which registered</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--Security12bTitle_c20240208__20240208_zqiJM6jY1F43"><ix:nonNumeric contextRef="AsOf2024-02-08" name="dei:Security12bTitle" id="ixv-333">Common Stock, par value $0.001 per share</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--TradingSymbol_c20240208__20240208_zbrsPPW8tJAe"><ix:nonNumeric contextRef="AsOf2024-02-08" name="dei:TradingSymbol" id="ixv-334">ABVC</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The <span id="xdx_904_edei--SecurityExchangeName_c20240208__20240208_zksQITkhV8Ni"><ix:nonNumeric contextRef="AsOf2024-02-08" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="ixv-335">Nasdaq</ix:nonNumeric></span> Stock Market LLC</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule
12b&#8211;2 of the Securities Exchange Act of 1934 (&#167; 240.12b&#8211;2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company <span id="xdx_908_edei--EntityEmergingGrowthCompany_c20240208__20240208_znisNoOQQK6g"><ix:nonNumeric contextRef="AsOf2024-02-08" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany" id="ixv-336">&#9744;</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 1.01 Entry into Material Definitive Agreements</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 06, 2024, ABVC BioPharma, Inc. (the
&#8220;<b>Company</b>&#8221;) entered into a definitive agreement with Shuling Jiang (&#8220;<b>Jiang</b>&#8221;), pursuant to which Jiang
shall transfer the ownership of certain land she owns located at Taoyuan City, Taiwan (the &#8220;<b>Land</b>&#8221;) to the Company (the
&#8220;<b>Agreement</b>&#8221;). Jiang is a director of the Company, is married to TS Jiang, the Company&#8217;s Chief Strategic Officer
and owns approximately 10% of the Company&#8217;s issued and outstanding shares of common stock. Accordingly, the transaction contemplated
by the Agreement constitutes a related party transaction as defined by Item&#160;404&#160;of&#160;Regulation S-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In consideration for the Land, the Company shall
pay Jiang (i) 703,495 restricted shares of the Company&#8217;s common stock (the &#8220;<b>Shares</b>&#8221;) at a price of $3.50 per
share and (ii) five-year warrants to purchase up to 1,000,000 shares of the Company&#8217;s common stock, with an exercise price of $2.00
per share. Under the Agreement, Jiang will also transfer outstanding liability owed on the Land (approximately $500,000) to the Company.
Thus, the parties value the exchange at approximately $2,962,232.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Agreement also contains
customary termination provisions, and other obligations and rights of the parties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The transaction contemplated by the Agreement
is intended to close on or before March 10, 2024, although the parties can negotiate an extension if necessary.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing description of the Agreement and
Warrants is qualified by reference to the full text of the Agreement and Form of Warrant, both of which are filed as exhibits hereto and
incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Neither this Current Report on Form 8-K, nor any
exhibit attached hereto, is an offer to sell or the solicitation of an offer to buy the Securities described herein. Such disclosure does
not constitute an offer to sell, or the solicitation of an offer to buy nor shall there be any sales of the Company&#8217;s securities
in any state in which such an offer, solicitation or sale would be unlawful. The securities mentioned herein have not been registered
under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or
an applicable exemption from the registration requirements under the Securities Act and applicable state securities laws.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 3.02 Unregistered Sales of Equity Securities.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information contained above under Item 1.01,
to the extent applicable, is hereby incorporated by reference herein. The issuance of the Shares and warrants pursuant to the Agreement
was made in reliance on the exemption afforded by Section 4(a)(2) of the Securities Act and Regulation S under the Securities Act and
corresponding provisions of state securities or &#8220;blue sky&#8221; laws. None of the securities have been registered under the Securities
Act or any state securities laws and may not be offered or sold in the United States absent registration with the SEC or an applicable
exemption from the registration requirements. The sale of the securities did not involve a public offering and was made without general
solicitation or general advertising.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 8.01 Other Events.</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 8, 2024, the Company issued a press
release regarding the land acquisitions. A copy of the press release is filed hereto as Exhibit 99.1, and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 9.01 Exhibits </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit No.</b></span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="text-align: justify">&#160;</td>
    <td><a href="ea193134ex4-1_abvcbio.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>10.1</td>
    <td style="text-align: justify">&#160;</td>
    <td><a href="ea193134ex10-1_abvcbio.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitive Agreement</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></td>
    <td style="text-align: justify">&#160;</td>
    <td><a href="ea193134ex99-1_abvcbio.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File, formatted in Inline XBRL</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ABVC BioPharma, Inc.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 8, 2024</span></td>
    <td style="width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; width: 36%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Uttam Patil</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Uttam Patil</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">2</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>ea193134ex4-1_abvcbio.htm
<DESCRIPTION>FORM OF WARRANT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 4.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">THIS WARRANT HAS NOT BEEN REGISTERED WITH THE
SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE
SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO
AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT
TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL
OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">The number
of shares of common stock issuable upon exercise of this warrant may be less than the amounts set forth on the face hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Warrant is issued pursuant to that certain
Definitive Agreement dated February 6, 2024 by and between the Company and the Holder (as defined below) (the &ldquo;<U>Agreement</U>&rdquo;).
Capitalized terms used and not otherwise defined herein shall have the meanings set forth for such terms in the Agreement. Receipt of
this Warrant by the Holder shall constitute acceptance and agreement to all of the terms contained herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">No. [ &nbsp;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ABVC
BIOPHARMA, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>COMMON STOCK PURCHASE WARRANT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ABVC BioPharma, Inc., a Nevada
corporation (together with any corporation which shall succeed to or assume the obligations of ABVC BioPharma, Inc. hereunder, the &ldquo;<U>Company</U>&rdquo;),
hereby certifies that, for value received, [Holder] (the &ldquo;<U>Holder</U>&rdquo;), is entitled, subject to the terms set forth below,
to purchase from the Company at any time during the Exercise Period (as defined in <U>Section 9</U>) up to <U>one million (1,000,000)</U>&bull;]
fully paid and non-assessable shares of Common Stock (as defined in <U>Section&nbsp;9</U>), at a purchase price per share equal to the
Exercise Price (as defined in <U>Section 9</U>). The number of shares of Common Stock for which this Common Stock Purchase Warrant (this
&ldquo;<U>Warrant</U>&rdquo;) is exercisable and the Exercise Price are subject to adjustment as provided herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.&nbsp;<U>DEFINITIONS</U>.
Certain terms are used in this Warrant as specifically defined in <U>Section 9</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.&nbsp;<U>EXERCISE
OF WARRANT</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.1.&nbsp;<U>Exercise</U>.
This Warrant may be exercised prior to its expiration pursuant to <U>Section 2.5</U> hereof by the Holder at any time or from time to
time during the Exercise Period, by submitting the form of subscription attached hereto (the &ldquo;<U>Exercise Notice</U>&rdquo;) duly
executed by the Holder, to the Company at its principal office, indicating whether the Holder is electing to purchase a specified number
of shares by paying the Aggregate Exercise Price as provided in <U>Section 2.2</U>. On or before the first Trading Day following the date
on which the Company has received the Exercise Notice, the Company shall transmit by electronic mail an acknowledgement of confirmation
of receipt of the Exercise Notice. Subject to <U>Section 2.4</U>, this Warrant shall be deemed exercised for all purposes as of the close
of business on the day on which the Holder has delivered the Exercise Notice to the Company. The Aggregate Exercise Price, if any, shall
be paid by wire transfer to the Company within five (5) Business Days of the date of exercise and prior to the time the Company issues
the certificates evidencing the shares issuable upon such exercise. In the event this Warrant is not exercised in full, the Company may,
at its expense, require the Holder, after such partial exercise, to promptly return this Warrant to the Company and the Company will forthwith
issue and deliver to or upon the order of the Holder a new Warrant or Warrants of like tenor, in the name of the Holder or as the Holder
(upon payment by the Holder of any applicable transfer taxes) may request, calling in the aggregate on the face or faces thereof for the
number of shares of Common Stock equal (without giving effect to any adjustment therein) to the number of such shares called for on the
face of this Warrant minus the number of such shares (without giving effect to any adjustment therein) for which this Warrant shall have
been exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.2.&nbsp;<U>Payment
of Exercise Price by Wire Transfer</U>. If the Holder elects to purchase a specified number of shares by paying the Aggregate Exercise
Price, the Holder shall pay such amount by wire transfer of immediately available funds to the account designated by the Company in its
acknowledgement of receipt of such Exercise Notice pursuant to <U>Section 2.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.3.&nbsp;<U>Intentionally
Omitted</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.4.&nbsp;<U>Antitrust
Notification</U>. If the Holder determines, in its sole judgment upon the advice of counsel, that the issuance of any Warrant Shares pursuant
to the terms hereof would be subject to the provisions of the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the &ldquo;<U>HSR
Act</U>&rdquo;), the Company shall file as soon as practicable after the date on which the Company receives notice from the Holder of
the applicability of the HSR Act and a request to so file with the United States Federal Trade Commission and the United States Department
of Justice the notification and report form required to be filed by it pursuant to the HSR Act in connection with such issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.5.&nbsp;<U>Termination</U>.
This Warrant shall terminate upon the earlier to occur of (i) exercise in full or (ii) the expiration of the Exercise Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.&nbsp;<U>INTENTIONALLY
OMITTED</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.&nbsp;<U>DELIVERY
OF STOCK CERTIFICATES ON EXERCISE</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.1.&nbsp;<U>Delivery
of Exercise Shares</U>. As soon as practicable after any exercise of this Warrant and in any event within three (3) Trading Days thereafter
(such date, the &ldquo;<U>Exercise Share Delivery Date</U>&rdquo;), the Company shall, at its expense (including the payment by it of
any applicable issue or stamp taxes), cause to be issued in the name of and delivered to the Holder, or as the Holder may direct, a certificate
or certificates evidencing the number of fully paid and non-assessable shares of Common Stock (which number shall be rounded down to the
nearest whole share in the event any fractional share may otherwise be issuable upon such exercise and the Company shall pay a cash adjustment
to the Holder in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price) to which the Holder
shall be entitled on such exercise, in such denominations as may be requested by the Holder, which certificate or certificates shall be
free of restrictive and trading legends (except for any such legends as may be required under the Securities Act). In lieu of delivering
physical certificates for the shares of Common Stock issuable upon any exercise of this Warrant, provided the Warrant Shares are not restricted
securities and the Company&rsquo;s transfer agent is participating in the Depository Trust Company (&ldquo;<U>DTC</U>&rdquo;) Fast Automated
Securities Transfer program or a similar program, upon request of the Holder, the Company shall cause its transfer agent to electronically
transmit such shares of Common Stock issuable upon exercise of this Warrant to the Holder (or its designee), by crediting the account
of the Holder&rsquo;s (or such designee&rsquo;s) broker with DTC through its Deposit Withdrawal Agent Commission system (provided that
the same time periods herein as for stock certificates shall apply) as instructed by the Holder (or its designee).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.2.&nbsp;<U>Intentionally
Omitted</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.3.&nbsp;<U>Charges,
Taxes and Expenses</U>. Issuance of Exercise Shares shall be made without charge to the Holder for any issue or transfer tax or other
incidental expense in respect of the issuance of such Exercise Shares, all of which taxes and expenses shall be paid by the Company, and
such Exercise Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder;&nbsp;<U>provided</U>,&nbsp;<U>however</U>,
that in the event Exercise Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise
shall be accompanied by the Assignment Form attached hereto (the &ldquo;<U>Assignment Form</U>&rdquo;) duly executed by the Holder and
the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5.&nbsp;<U>CERTAIN
ADJUSTMENT</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.1.&nbsp;<U>Stock
Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (a) pays a stock dividend or otherwise makes
a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of
Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (b) subdivides outstanding shares of Common Stock into a larger number of shares, (c) combines (including by way of reverse
stock split) outstanding shares of Common Stock into a smaller number of shares, or (d) issues by reclassification of shares of the Common
Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the
numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event
and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event and the number of
shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant
shall remain unchanged. Any adjustment made pursuant to this <U>Section 5.1</U> shall become effective immediately after the record date
for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the
effective date in the case of a subdivision, combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.2&nbsp;<U>Pro
Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution
of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including,
without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification,
corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;), at any time after
the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent
that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise
of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation)
immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the
record holders of shares of Common Stock are to be determined for the participation in such Distribution (provided, however, that, to
the extent that the Holder&rsquo;s right to participate in any such Distribution would result in the Holder exceeding the beneficial ownership
limitation provided for in <U>Section 10</U>, then the Holder shall not be entitled to participate in such Distribution to such extent
(or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such
Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in
the Holder exceeding the beneficial ownership limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.3&nbsp;<U>Fundamental
Transaction</U>. If, at any time while this Warrant is outstanding, (a) the Company effects any merger or consolidation of the Company
with or into another Person, (b) the Company effects any sale of all or substantially all of its assets in one or a series of related
transactions, (c) any tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders
of Common Stock are permitted to tender or exchange their shares for other securities, cash or property, or (d) the Company effects any
reclassification of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into
or exchanged for other securities, cash or property (each, a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon the closing of
a Fundamental Transaction and payment of the exercise price therefore, the Holder shall have the right to receive, for each Warrant Share
that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of
the Holder (without regard to any limitation in Section 10 on the exercise of this Warrant), the number of shares of Common Stock of the
successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate
Consideration</U>&rdquo;) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for
which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 10 on
the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted
to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock
in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable
manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given
any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same
choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.4&nbsp;<U>Intentionally
Omitted</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.5&nbsp;<U>Calculations</U>.
All calculations under this <U>Section 5</U> shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be.
For purposes of this <U>Section 5</U>, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall
be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding at the close of the Trading
Day on or, if not applicable, most recently preceding, such given date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.6&nbsp;<U>Notice
to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) &nbsp;<U>Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this <U>Section 5</U>, the Company shall promptly
mail to the Holder a notice setting forth the Exercise Price after such adjustment and setting forth a brief statement of the facts requiring
such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) &nbsp;<U>Notice
to Allow Exercise by Holder</U>. If (i) the Company shall declare a dividend (or any other distribution in whatever form) on the Common
Stock; (ii) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock; (iii) the Company shall
authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock
of any class or of any rights; (iv) the approval of any stockholders of the Company shall be required in connection with any reclassification
of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of
the assets of the Company, of any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property;
or (v) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company;
then, in each case, the Company shall cause to be mailed to the Holder at its last address as it shall appear upon the Warrant Register
of the Company, at least twenty (20) calendar days prior to the applicable record or effective date hereinafter specified, a notice stating
(x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a
record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions,
redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer
or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of
record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification,
consolidation, merger, sale, transfer or share exchange; provided that the failure to mail such notice or any defect therein or in the
mailing thereof shall not affect the validity of the corporate action required to be specified in such notice. Subject to applicable law,
the Holder is entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event
triggering such notice. Notwithstanding the foregoing, the delivery of the notice described in this <U>Section 5.6</U> is not intended
to and shall not bestow upon the Holder any voting rights whatsoever with respect to outstanding unexercised Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6.&nbsp;<U>NO
IMPAIRMENT</U>. The Company will not, by amendment of the Articles of Incorporation or through any reorganization, transfer of assets,
consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or
performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and
in taking all such action as may be necessary or appropriate in order to protect the rights of the Holder against impairment. Without
limiting the generality of the foregoing, the Company (a) will not increase the par value of any shares of Common Stock receivable on
the exercise of this Warrant above the amount payable therefor on such exercise and (b) will take all such action as may be necessary
or appropriate in order that the Company may validly and legally issue fully paid and non-assessable shares of stock on the exercise of
this Warrant from time to time outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7.&nbsp;<U>NOTICES
OF RECORD DATE</U>. In the event of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;any
taking by the Company of a record of the holders of any class of securities for the purpose of determining the holders thereof who are
entitled to receive any dividend or other distribution, or any right to subscribe for, purchase or otherwise acquire any shares of stock
of any class or any other securities or property, or to receive any other right;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;any
capital reorganization of the Company, any reclassification or recapitalization of the capital stock of the Company or any transfer of
all or substantially all the assets of the Company to or any consolidation or merger of the Company with or into any other Person or any
other Change of Control; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;any
voluntary or involuntary dissolution, liquidation or winding-up of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">then, and in each such event, the Company will
mail or cause to be mailed to the Holder a notice specifying (i) the date on which any such record is to be taken for the purpose of such
dividend, distribution or right, and stating the amount and character of such dividend, distribution or right, or (ii) the date on which
any such reorganization, reclassification, recapitalization, transfer, consolidation, merger, dissolution, liquidation or winding-up is
anticipated to take place, and the time, if any is to be fixed, as of which the holders of record of Common Stock shall be entitled to
exchange their shares of Common Stock for securities or other property deliverable on such reorganization, reclassification, recapitalization,
transfer, consolidation, merger, dissolution, liquidation or winding-up. Such notice shall be mailed at least fifteen (15) days prior
to the date specified in such notice on which any such action is to be taken.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">8.&nbsp;<U>RESERVATION
OF STOCK ISSUABLE ON EXERCISE OF WARRANT; REGULATORY COMPLIANCE</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.1.&nbsp;<U>Reservation
of Stock Issuable on Exercise of Warrant</U>. The Company shall at all times while this Warrant shall be outstanding, reserve and keep
available out of its authorized but unissued Common Stock, such number of shares of Common Stock as shall from time to time be sufficient
to effect the exercise of all or any portion of the Warrant Shares (disregarding for this purpose any and all limitations of any kind
on such exercise). The Company shall, from time to time in accordance with the Delaware General Corporation Law, increase the authorized
number of shares of Common Stock or take other effective action if at any time the unissued number of authorized shares shall not be sufficient
to satisfy the Company&rsquo;s obligations under this <U>Section 8</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.2.&nbsp;<U>Regulatory
Compliance</U>. If any shares of Common Stock to be reserved for the purpose of exercise of the Warrant Shares require registration or
listing with or approval of any Governmental Authority, stock exchange or other regulatory body under any federal or state law or regulation
or otherwise before such shares may be validly issued or delivered upon exercise, the Company shall, at its sole cost and expense, in
good faith and as expeditiously as possible, secure such registration, listing or approval, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">9.&nbsp;<U>DEFINITIONS</U>.
As used herein the following terms, unless the context otherwise requires, have the following respective meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo;
means a Person that directly, or indirectly through one or more intermediaries, controls or is controlled by, or is under common control
with, the Person specified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<FONT STYLE="font-size: 10pt"><U>Aggregate
Exercise Price</U></FONT>&rdquo; <FONT STYLE="font-size: 10pt">means, in connection with the exercise of this Warrant at any time, an
amount equal to the product obtained by multiplying (i) the Exercise Price times (ii) the number of shares of Common Stock for which this
Warrant is being exercised at such time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Articles of Incorporation</U>&rdquo;
means the Company&rsquo;s Restated Articles of Incorporation as amended to date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Business Day</U>&rdquo;
means any day other than a Saturday, Sunday or any other day on which banks are permitted or required to be closed in New York City.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common Stock</U>&rdquo;
means (i) the Company&rsquo;s Common Stock, $0.001 par value per share, and (ii) any other securities into which or for which any of the
securities described in clause (i) above have been converted or exchanged pursuant to a plan of recapitalization, reorganization, merger,
sale of assets or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Convertible Securities</U>&rdquo;
means any debt, equity or other securities that are, directly or indirectly, convertible into or exchangeable for Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exchange Act</U>&rdquo;
means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder from time to time in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exercise Period</U>&rdquo;
means the period commencing on the Issue Date and ending 11:59 P.M. (New York City time) on the date that is sixty (60) months from the
Issue Date or earlier closing of a Fundamental Transaction (other than a Fundamental Transaction of the type described in clause (d) of
the definition thereof resulting in the conversion into or exchange for another security of the Company).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exercise Price</U>&rdquo;
means $2.00 per share, as may be adjusted pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exercise Shares</U>&rdquo;
means the shares of Common Stock for which this Warrant is then being exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Fair Market Value</U>&rdquo;
means, with respect to any security or other property, the fair market value of such security or other property as determined by the Board
of Directors, acting in good faith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Governmental Authority</U>&rdquo;
means the government of the United States or any other nation, or of any political subdivision thereof, whether state or local, and any
agency, authority, instrumentality, regulatory body, court, central bank or other entity exercising executive, legislative, judicial,
taxing, regulatory or administrative powers or functions of or pertaining to government (including any supra-national bodies such as the
European Union or the European Central Bank).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Issue Date</U>&rdquo;
means February 6, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<FONT STYLE="font-size: 10pt"><U>Person</U></FONT>&rdquo;
<FONT STYLE="font-size: 10pt">means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint
venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities Act</U>&rdquo;
means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder from time to time in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subsidiary</U>&rdquo;
means, as of any time of determination and with respect to any Person, any United States corporation, partnership, limited liability company
or limited liability partnership, all of the stock (or other equity interest) of every class of which, except directors&rsquo; qualifying
shares (or any equivalent), shall, at such time, be owned by such Person either directly or through Subsidiaries and of which such Person
or a Subsidiary shall have 100% control thereof, except directors&rsquo; qualifying shares. Unless the context otherwise clearly requires,
any reference to a &ldquo;Subsidiary&rdquo; is a reference to a Subsidiary of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading Day</U>&rdquo;
means a day on which the Common Stock is traded on a Trading Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading Market</U>&rdquo;
means whichever of the New York Stock Exchange, NYSE: Amex Exchange, or the Nasdaq Stock Market (including the Nasdaq Capital Market),
on which the Common Stock is listed or quoted for trading on the date in question.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo;
means, as of any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of one share of Common Stock trading in the ordinary course of
business on the applicable Trading Price for such date (or the nearest preceding date) on such Trading Market as reported by Bloomberg
Financial L.P.; (b) if the Common Stock is not then listed on a Trading Market and if the Common Stock is traded in the over-the-counter
market, as reported by the OTC Bulletin Board, the volume weighted average price of one share of Common Stock for such date (or the nearest
preceding date) on the OTC Bulletin Board, as reported by Bloomberg Financial L.P.; (c) if the Common Stock is not then listed or quoted
on the OTC Bulletin Board and if prices for the Common Stock is then reported in the &ldquo;Pink Sheets&rdquo; published by the Pink OTC
Markets Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price of one share
of Common Stock so reported, as reported by Bloomberg Financial L.P.; or (d) in all other cases, the fair market value of one share of
Common Stock as determined by an independent appraiser selected in good faith by the Holder and reasonably acceptable to the Company (in
each case rounded to four decimal places).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<FONT STYLE="font-size: 10pt"><U>Warrant
Shares</U></FONT>&rdquo; <FONT STYLE="font-size: 10pt">means collectively the shares of Common Stock of the Company issuable upon exercise
of the Warrant in accordance with its terms, as such number may be adjusted pursuant to the provisions thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">10.&nbsp;<U>LIMITATION
ON BENEFICIAL OWNERSHIP</U>. Notwithstanding anything to the contrary contained herein, the Holder shall not be entitled to receive shares
of Common Stock or other securities (together with Common Stock, &ldquo;<U>Equity Interests</U>&rdquo;) upon exercise of this Warrant
to the extent (but only to the extent) that such exercise or receipt would cause the Holder Group to become, directly or indirectly, a
&ldquo;beneficial owner&rdquo; (within the meaning of Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder)
of a number of Equity Interests of a class that is registered under the Exchange Act which exceeds the Maximum Percentage (as defined
below) of the Equity Interests of such class that are outstanding at such time. Any purported delivery of Equity Interests in connection
with the exercise of the Warrant prior to the termination of this restriction in accordance herewith shall be void and have no effect
to the extent (but only to the extent) that such delivery would result in the Holder Group becoming the beneficial owner of more than
the Maximum Percentage of the Equity Interests of a class that is registered under the Exchange Act that is outstanding at such time.
If any delivery of Equity Interests owed to the Holder following exercise of this Warrant is not made, in whole or in part, as a result
of this limitation, the Company&rsquo;s obligation to make such delivery shall not be extinguished and the Company shall deliver such
Equity Interests as promptly as practicable after the Holder gives notice to the Company that such delivery would not result in such limitation
being triggered or upon termination of the restriction in accordance with the terms hereof. To the extent limitations contained in this
<U>Section 10</U> apply, the determination of whether this Warrant is exercisable and of which portion of this Warrant is exercisable
shall be the sole responsibility and in the sole determination of the Holder, and the submission of an Exercise Notice shall be deemed
to constitute the Holder&rsquo;s determination that the issuance of the full number of Warrant Shares requested in the Exercise Notice
is permitted hereunder, and neither the Company nor any Warrant agent shall have any obligation to verify or confirm the accuracy of such
determination. For purposes of this <U>Section 10</U>, (i) the term &ldquo;<U>Maximum Percentage</U>&rdquo; shall mean 4.99%; provided,
that if at any time after the date hereof the Holder Group beneficially owns in excess of 4.99% of any class of Equity Interests in the
Company that is registered under the Exchange Act (excluding any Equity Interests deemed beneficially owned by virtue of this Warrant),
then the Maximum Percentage shall automatically increase to 9.99% so long as the Holder Group owns in excess of 4.99% of such class of
Equity Interests (and shall, for the avoidance of doubt, automatically decrease to 4.99% upon the Holder Group ceasing to own in excess
of 4.99% of such class of Equity Interests); and (ii) the term &ldquo;<U>Holder Group</U>&rdquo; shall mean the Holder plus any other
Person with which the Holder is considered to be part of a group under Section 13 of the Exchange Act or with which the Holder otherwise
files reports under Sections 13 and/or 16 of the Exchange Act. In determining the number of Equity Interests of a particular class outstanding
at any point in time, the Holder may rely on the number of outstanding Equity Interests of such class as reflected in (x) the Company&rsquo;s
most recent Annual Report on Form 10-K or Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, as the case
may be, (y) a more recent public announcement by the Company or (z) a more recent notice by the Company or its transfer agent to the Holder
setting forth the number of Equity Interests of such class then outstanding. For any reason at any time, upon written or oral request
of the Holder, the Company shall, within one (1) Trading Day of such request, confirm orally and in writing to the Holder the number of
Equity Interests of any class then outstanding. The provisions of this <U>Section 10</U> shall be construed, corrected and implemented
in a manner so as to effectuate the intended beneficial ownership limitation herein contained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">11.&nbsp;<U>REGISTRATION
AND TRANSFER OF WARRANT</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.1.&nbsp;<U>Registration
of Warrant</U>. The Company shall register and record transfers, exchanges, reissuances and cancellations of this Warrant, upon the records
to be maintained by the Company for that purpose, in the name of the record holder hereof from time to time. The Company may deem and
treat the registered holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to
the Holder, and for all other purposes, absent actual notice to the contrary. The Company shall be entitled to rely, and held harmless
in acting or refraining from acting in reliance upon, any notices, instructions or documents it believes in good faith to be from an authorized
representative of the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.2&nbsp;<U>Transferability</U>.
This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part,
upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this
Warrant substantially in the form of assignment (the &ldquo;<U>Assignment Notice</U>&rdquo;) attached hereto duly executed by the Holder
or its agent or attorney. The Company may require the transferor thereof to provide to the Company an opinion of counsel selected by the
transferor, the form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect that such transfer
does not require registration of the transferred Warrant under the 1933 Act. Upon such surrender, the Company shall execute and deliver
a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified
in such Assignment Notice, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this
Warrant shall promptly be cancelled. This Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the
purchase of Exercise Shares without having a new Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.3.&nbsp;<U>New
Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company,
together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or
its agent or attorney. Subject to compliance with <U>Section 11.2</U>, as to any transfer which may be involved in such division or combination,
the Company shall execute and deliver a new Warrant or Warrants in exchange for this Warrant or Warrants to be divided or combined in
accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the original Issue Date and shall be identical
with this Warrant except as to the number of Exercise Shares issuable pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">12.&nbsp;<U>LOSS,
THEFT, DESTRUCTION OR MUTILATION OF WARRANT</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Exercise Shares, and in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of this Warrant, shall not include
the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make
and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">13.&nbsp;<U>REMEDIES</U>.
The Company stipulates that the remedies at law of the Holder in the event of any default or threatened default by the Company in the
performance of or compliance with any of the terms of this Warrant are not and will not be adequate, and that such terms may be specifically
enforced by a decree for the specific performance of any agreement contained herein or by an injunction against a violation of any of
the terms hereof or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">14.&nbsp;<U>NO
RIGHTS AS A STOCKHOLDER</U>. Except as otherwise specifically provided herein, the Holder, solely in such Person&rsquo;s capacity as a
holder of this Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of share capital of the Company for
any purpose, nor shall anything contained in this Warrant be construed to confer upon the Holder, solely in such Person&rsquo;s capacity
as the Holder of this Warrant, any of the rights of a stockholder of the Company or any right to vote, give or withhold consent to any
corporate action (whether any reorganization, issue of stock, reclassification of stock, consolidation, merger, conveyance or otherwise),
receive notice of meetings, receive dividends or subscription rights, or otherwise, prior to the issuance to the Holder of the Exercise
Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">15.&nbsp;<U>NOTICES</U>.
All notices, requests, demands and other communications that are required or may be given pursuant to the terms of this Warrant shall
be in writing and shall be deemed delivered (i) on the date of delivery when delivered by hand on a Business Day during normal business
hours or, if delivered on a day that is not a Business Day or after normal business hours, then on the next Business Day, (ii) on the
date of transmission when sent by facsimile transmission or email during normal business hours on a Business Day with telephone confirmation
of receipt or, if transmitted on a day that is not a Business Day or after normal business hours, then on the next Business Day, or (iii)
on the second Business Day after the date of dispatch when sent by a reputable courier service that maintains records of receipt. The
addresses for notice shall be as set forth in the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">16.&nbsp;<U>CONSENT
TO AMENDMENTS</U>. Any term of this Warrant may be amended, and the Company may take any action herein prohibited, or compliance therewith
may be waived, only if the Company shall have obtained the written consent (and not without such written consent) to such amendment, action
or waiver from the Holder. No course of dealing between the Company and the Holder nor any delay in exercising any rights hereunder shall
operate as a waiver of any rights of the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">17.&nbsp;<U>MISCELLANEOUS</U>.
In case any provision of this Warrant shall be invalid, illegal or unenforceable, or partially invalid, illegal or unenforceable, the
provision shall be enforced to the extent, if any, that it may legally be enforced and the validity, legality and enforceability of the
remaining provisions shall not in any way be affected or impaired thereby. If any provision of this Warrant is found to conflict with
the Agreement, the provisions of this Warrant shall prevail. THIS WARRANT SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH, AND THE
RIGHTS OF THE PARTIES SHALL BE GOVERNED BY, THE INTERNAL LAW OF THE STATE OF NEW YORK EXCLUDING CHOICE-OF-LAW PRINCIPLES OF THE LAW OF
SUCH STATE THAT WOULD PERMIT THE APPLICATION OF THE LAWS OF A JURISDICTION OTHER THAN SUCH STATE. The headings in this Warrant are for
purposes of reference only, and shall not limit or otherwise affect any of the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>[Remainder of Page Intentionally Left Blank]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its duly authorized officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dated as of February 6, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-transform: uppercase">ABVC BIOPHARMA, INC.</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-transform: uppercase">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD>Uttam Patil</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Chief Executive Officer</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Options: NewSection; Value: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">FORM OF SUBSCRIPTION</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(To be signed only on exercise</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">of Common Stock Purchase Warrant)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">TO:</TD><TD STYLE="text-align: justify">ABVC BioPharma, Inc.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.&nbsp;The
undersigned Holder of the attached Warrant hereby elects to exercise its purchase right under such Warrant to purchase shares of Common
Stock of ABVC BioPharma, Inc., a Nevada corporation (the &ldquo;<U>Company</U>&rdquo;), as follows (check one or more, as applicable):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&#9744;</TD><TD STYLE="text-align: justify">to exercise the Warrant to purchase __________ shares of Common Stock and to pay the Aggregate Exercise
Price therefor by wire transfer of United States funds to the account of the Company, which transfer has been made prior to or as of the
date of delivery of this Form of Subscription pursuant to the instructions of the Company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">and/or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&#9744;</TD><TD STYLE="text-align: justify"></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.&nbsp;In
exercising this Warrant, the undersigned Holder hereby confirms and acknowledges that the shares of Common Stock are being acquired solely
for the account of the undersigned and not as a nominee for any other party, and for investment, and that the undersigned shall not offer,
sell or otherwise dispose of any such shares of Common Stock except under circumstances that will not result in a violation of the Securities
Act or any state securities laws. The undersigned hereby further confirms and acknowledges that it is an &ldquo;accredited investor&rdquo;,
as that term is defined under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.&nbsp;Please
issue a stock certificate or certificates representing the appropriate number of shares of Common Stock in the name of the undersigned
or in such other name(s) as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 6%">Name:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 30%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>Address:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>TIN:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 243pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 243pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%">(Signature must conform exactly to name of Holder as specified on the face of the Warrant)</TD>
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="width: 40%">Dated:&nbsp;&nbsp;_________________</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM OF ASSIGNMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(To be signed only on transfer of Warrant)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For value received, the undersigned
hereby sells, assigns, and transfers unto ________________ the right represented by the within Warrant to purchase <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
shares of Common Stock of ABVC BioPharma, Inc., a Nevada corporation, to which the within Warrant relates, and appoints _________________
attorney to transfer such right on the books of ABVC BioPharma, Inc., with full power of substitution in the premises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">[insert name of Holder]</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 60%">Dated:___________________</TD>
    <TD STYLE="width: 4%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 36%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">[insert address of Holder]</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Signed in the presence of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">__________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>ea193134ex10-1_abvcbio.htm
<DESCRIPTION>DEFINITIVE AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt"><B>Exhibit 10.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Definitive
Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Definitive Agreement (&ldquo;<U>Agreement</U>&rdquo;) is entered into as of February 06, 2024, by and between ABVC BioPharma, Inc. (&ldquo;<U>ABVC</U>&rdquo;),
and Shuling Jiang (hereinafter referred to as &ldquo;<U>Shuling</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABVC
and Shuling are sometimes referred to herein individually as a &ldquo;<U>Party</U>,&rdquo; and collectively as the &ldquo;<U>Parties</U>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to strategically cooperate and construct an integrated platform for the global development of the healthcare business and the medical,
pharmaceutical, and biotechnology in Taiwan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
1: Subject Matter and Consideration</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject Matter: The subject matter of this Agreement includes:</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
The common shares of ABVC (stock symbol: ABVC) on the Nasdaq Capital Market, with a price of US$3.50 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
Shuling&rsquo;s ownership of a property located at Taoyuan City, Taiwan (hereinafter referred to as The Land or The Property).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 20, 2023, the valuation of the Land is NT$ 88,866,964 or approximately US$2,962,232 (see Exhibit A).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consideration: The consideration for this Agreement shall be as follows:</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
ABVC shall issue 703,495 common shares to Shuling Jiang at a price of US$3.50 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
ABVC agrees to provide 1,000,000 warrants, with an exercise price of US$2.00 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
Shuling Jiang shall transfer the NT$15,000,000 or approximately US$500,000 bank liability of the land to ABVC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
Shuling Jiang shall transfer ownership of The Land to ABVC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.3
Transfer of Ownership: Upon completion of the transaction, ownership of the ABVC Shares shall be transferred from ABVC to Shuling, and
ownership of The Land shall be transferred from Shuling to ABVC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
2: Exchange of The Land through ABVC Equity Transfer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1
Agreement to Exchange The Land: ABVC and Shuling agree to exchange ownership in Shuling&rsquo;s real estate The Land through an equity
transfer of ABVC shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2
Value of the Exchange: The value of the exchange is estimated to be approximately US$2,962,232, equivalent to 703,495 shares of ABVC
common stock at US$3.50 per share and $500,000 Bank Loan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shuling
agrees the ABVC Shares are restricted securities to be issued in accordance with Regulation S promulgated under the Securities Act of
1933.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3
Transfer Process: The transfer of ABVC Shares from ABVC to Shuling shall be executed in accordance with the applicable laws, regulations,
and procedures governing equity transfers, as well as Regulation S promulgated under the Securities Act of 1933.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4
Transfer of Ownership: Upon completion of the equity transfer, the ownership stake in Shuling&rsquo;s real estate The Property shall
be transferred from Shuling to ABVC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5
Representation of Value: Both parties acknowledge and agree that the value of the exchange is based on the estimated value of The Property
and the market value of ABVC shares at the time of the equity transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.6
Valuation Dispute: In the event of any dispute regarding the valuation or other matters related to the exchange, the parties shall make
good faith efforts to resolve the dispute through negotiation and mediation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.7
Taxes and Fees: Any taxes, fees, or other charges arising from the equity transfer and exchange shall be the responsibility of the respective
parties as determined by applicable laws and regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
3: Capital Protection Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1
Valuation Assessment: In the event of a dispute regarding the valuation or value maintenance, the parties may engage an independent third-party
expert or appraiser to assess the value and provide recommendations for adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2
Amendments to the Agreement: Any amendments or modifications to the definitive agreement necessitated by the value adjustment shall be
made in writing and signed by both parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3
Force Majeure: The provisions of the definitive agreement shall not apply in cases of force majeure events that are beyond the reasonable
control of either party and that significantly impact the value of The Land or stocks.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4
Governing Law and Jurisdiction: This Agreement shall be governed by and construed in accordance with the laws of the jurisdiction in
the State of New York. Any disputes arising from or in connection with this Agreement shall be subject to the exclusive jurisdiction
of the courts in that jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
4: Termination, Replacement and Amendment</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1
Both parties aim to complete the transfer of the target assets by March 10, 2024. If unable to do so, both parties shall negotiate and
determine a subsequent transfer date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2
Composition: Supplementary agreements or appended documents related to assets and equity transfer subsequently signed by both parties
shall constitute valid integral parts of this Agreement. The rights and obligations of both parties shall be subject to the terms and
conditions stipulated in this agreement and in any supplementary agreements or appended documents subsequently signed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3
Amendment: The terms and conditions in this Agreement can be further amended in writing upon the mutual agreement of both parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4
Termination: This Agreement shall become invalid or terminated and shall no longer have any effect. However, the provisions of Sections
3.6, Sections 4, Sections 5, and Sections 6 shall remain in effect after the termination or invalidation of this Memorandum of Understanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
5: Confidentiality</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1
Duty of Care: Both parties agree to exercise due care in maintaining the confidentiality of any relevant data or information. This duty
of confidentiality shall not be affected by the termination or expiration of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2
Non-Disclosure Obligation: Both parties shall keep all confidential information received from the other party confidential and shall
not disclose it to any third party without prior written consent, unless required by law or authorized by the disclosing party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3
Return or Destruction of Confidential Information: Upon the expiration, termination, or at the request of either party, the receiving
party shall promptly return to the disclosing party all confidential information received, along with any copies or reproductions thereof.
Alternatively, the receiving party shall follow the instructions of the disclosing party regarding the destruction of such confidential
information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.4
Survival of Confidentiality Obligations: The obligations of confidentiality and non-disclosure shall survive the expiration or termination
of this Agreement and shall continue to be binding on both parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.5
Exceptions: The obligations of confidentiality shall not apply to information that: (a) was already known to the receiving party prior
to its disclosure by the disclosing party; (b) is or becomes publicly available without breach of this Agreement; (c) is received from
a third party without breach of any confidentiality obligation; or (d) is independently developed by the receiving party without reference
to the disclosing party&rsquo;s confidential information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
6: Copies of the Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1
Two original copies of this Agreement have been prepared, with each party holding one original copy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2
After signing, each party shall retain the original copy held by them as valid evidence between the parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3
Copies, reproductions, or electronic files of this Agreement shall have the same legal effect and may be used for communication between
the parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature
Page</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Party A: ABVC BioPharma, Inc</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
Uttam Yashwant Patil, Ph.D.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: CEO</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Party
B: &#34083;&#28113;&#40801; Shuling Jiang</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>



<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="color: Black"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>ea193134ex99-1_abvcbio.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex99-1_001.jpg" ALT=""></P>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ABVC Acquires $2.96 Million Worth of Land
in Asia with Stocks<BR>
 Priced at $3.50 per Share</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Fremont, CA, February 08, 2024</B> &ndash;
ABVC BioPharma, Inc. (NASDAQ: ABVC) (&ldquo;Company&rdquo;), a clinical-stage biopharmaceutical company developing therapeutic solutions
in Oncology/Hematology, Neurology, and Ophthalmology, <FONT STYLE="background-color: white">announced today</FONT> that it signed a definitive
agreement to acquire real estate in Taoyuan City, Taiwan. The acquisition of real estate assets, estimated at approximately $2.96 million
via an equity transfer of $3.50 per share, is to develop plant factories for ABVC&rsquo;s botanical pipeline strategically; ABVC hopes
the property will ultimately be used as an integrated platform for the global development of the Asian healthcare business and the medical,
pharmaceutical, and biotechnology industries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The acquisition aims to establish a base for Good
Agricultural Practices (GAP) fields and an integrated platform for collaboration between researchers and industry leaders. ABVC will issue
the current land owner shares of ABVC common stock at $3.50 per share and a warrant to purchase up to 1,000,000 shares of common stock
in consideration for ownership of the property, which is estimated at $2.96 million by a third-party valuation company. This is a related
party transaction since the seller is one of ABVC&rsquo;s directors who owns approximately 10% of ABVC&rsquo;s issued and outstanding shares of common
stock and is married to ABVC&rsquo;s Chief Strategic Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">&ldquo;We are
pleased to add more value to our shareholders&rsquo; equity by executing this acquisition and appreciate the recognition of the stock price
of 150% higher than the current market price. ABVC aims to build on the fastest-growing Asian market for pharmaceutical products, medical
devices, and healthcare services. The Company will use the newly acquired land to serve as the base for plant factories and GAP to grow
the raw materials needed to develop the Company&rsquo;s botanical new drugs.&rdquo; said Dr. Uttam Patil, ABVC&rsquo;s Chief Executive Officer. &ldquo;We
will work towards developing the fields to cut costs on raw material purchases and continue cooperating and constructing an integrated
platform for the global development of Asian healthcare business and the medical, pharmaceutical, and biotechnology industries. We hope
this will provide a new avenue for collaboration between industry, academia, and research and revitalize Asia&rsquo;s promotion of innovation,
knowledge exchange, and sustainable development.&rdquo; </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">ABVC&rsquo;s
real estate investment raises the shareholders&rsquo; equity and facilitates ABVC&rsquo;s drug development plan, and ABVC believes
it will help generate revenue in the future. Following the pandemic, life sciences-related real estate in Asia has been considered a
hot spot. <FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>1 </SUP></FONT>According to that same article,
&ldquo;burgeoning demand for pharmaceuticals from a greying population; government policies to support the industry; a steady flow
of mergers and acquisitions; a rising number of listings; and the expansion of R&amp;D capacity&rdquo; has led to a demand for life
sciences real estate in Asia Pacific.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><SUP>1</SUP></TD><TD STYLE="text-align: justify">https://www.scmp.com/presented/business/topics/apac-life-sciences-opportunities/article/3157871/life-sciences-real</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">As noted
by Erik Hill, Managing Director and National Sector Lead of Healthcare and Life Science at Partner Valuation Advisory, investors
have come to appreciate the recession-resistant returns offered by healthcare real estate. <FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>2</SUP></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>ABVC urges its shareholders to sign up on the
Company&rsquo;s website for the latest news alerts. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">https://abvcpharma.com/?page_id=17707</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About ABVC BioPharma</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ABVC BioPharma is a clinical-stage biopharmaceutical
company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus<SUP>&reg;</SUP>) under development. For its drug
products, the Company utilizes in-licensed technology from its network of world-renowned research institutions to conduct proof-of-concept
trials through Phase II of clinical development. The Company&rsquo;s network of research institutions includes Stanford University, the University
of California at San Francisco, and Cedars-Sinai Medical Center. For Vitargus<SUP>&reg;</SUP>, the Company intends to conduct global clinical
trials through Phase III.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release contains &ldquo;forward-looking
statements.&rdquo; The words may precede such statements &ldquo;intends,&rdquo; &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;plans,&rdquo; &ldquo;expects,&rdquo;
&ldquo;anticipates,&rdquo; &ldquo;projects,&rdquo; &ldquo;predicts,&rdquo; &ldquo;estimates,&rdquo; &ldquo;aims,&rdquo; &ldquo;believes,&rdquo; &ldquo;hopes,&rdquo;
&ldquo;potential,&rdquo; or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions,
and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company&rsquo;s control, and cannot be predicted
or quantified, and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements.
None of the outcomes expressed herein are guaranteed. Such risks and uncertainties include, without limitation, risks and uncertainties
associated with (i) our inability to manufacture our product candidates on a commercial scale on our own, or in collaboration with third
parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition;
(iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to proceed to the next level
of the clinical trials or to market our product candidates. More detailed information about the Company and the risk factors that may
affect the realization of forward-looking statements is set forth in the Company&rsquo;s filings with the Securities and Exchange Commission
(SEC), including the Company&rsquo;s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors are urged to read these documents
free of charge on the SEC&rsquo;s website at&nbsp;http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Contact:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Leeds Chow</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Email: leedschow@ambrivis.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>2</SUP></FONT></TD><TD STYLE="text-align: justify">https://www.globest.com/2023/11/13/healthcare-real-estate-opportunities-beyond-medical-offices-and-hospitals/?slreturn=20240105041457</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  S &4# 2(  A$! Q$!_\0
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MWQQJH:R\)>%K($[WFU75GA^TM&&:TTR#4-0<>39RLO\ *_\ \$\=.UW]G?\
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M(M-0^?['<S7&FF^AAEE@>>")DYCX)?M'?\$R_P!G'X9^&O@]\%/CQ^S?\/\
MX=>$;:2VT/PYH_Q)\/-#"9Y7N+J[N[R\U:ZU'5-2OKB1[B^U/4[N[O[R9B]Q
M<2$+CV<-P[Q#C*%/$X3(,]Q>&K1YJ.(PN2YOB</5BI2CS4J^'RRO1JQYHRBY
M4ZLX\T91YN:,E'P<5Q5PO@<15PF.XFX<P6+H24*^%QF?Y)A,51FXQFH5L-BL
MWP]>E)QG"2C5HTY.,XRY>647+^=S]JC_ (*+?M?ZU^PI\8/V;+G_ (),?$7]
MG'X'7/P:U#X?/XL\KQ%:>%/A7X.CMK>S359;:X\,V5M]CTV)%:5[FZ1[B>0W
M%W/)))-(_P"@_P"Q_P#\JVW_ ':;^TM_ZE_Q9K]+/B_^U+_P3D^/'PQ\;_!S
MXI_M(? 7Q-\.OB-X?O?"WC'P^?BSI&F#5]#U%0EY9'4-(UNQU*T$RJ 9K*\M
MYU'W)5R:\]\%_$7_ ()5^!OV:C^R+X1^-_P%T_\ 9\'A+Q-X%/@1/C+!=QCP
MQXQO-7O_ !#I9UVZ\2S^(A]ONM=U24W']K?:[?[3MMIH4BB5,<?DN<Y5AI8S
M-,GS;+,'"=.G/%YEE>8Y?A8U*LG&E"6)QV!P>'C.K).-.$J\9U))QA&<DTL%
MQIP:]N+^%'Z<3\.O\L]9_.9_P30_9 _X(M?%C]C?X7^.?VPO&GPRT?X_:M=^
M,HO&-AXC^.$W@S5X+;3_ !AK5AX<^T^'EUFQ6R63P[;Z9+ P@Q<PR)<EV,I"
M_3/QW_81_P"#=?P]\'?B/KGAOXS_  _\,^)=*\(:]?>&M8\%_'R7Q1XH@\16
M^F7<NB0Z1X;;4]6&O7-UJ:VL T@6+_V@'^S&:V60SQ_47_# 7_!NC@ R?L_-
MM4*"W[2/C!CA0  2?B.2<  <FK5C^P;_ ,&ZEA>6U[$O[.LTEK-'.L-W^T3X
MKNK64QMN$=S;3?$5HKB!\8DAE5HY%RCJRD@^%]>P/_0;@_\ PKPW_P TC_UR
MX._Z*[A7_P 2;A[_ .?AZI_P;H>+?BCXH_X)O^%[;X@Q73>'?"OQ&\=^&/A+
MJ-[!]GGU#X>6-Y:W$*Q+M3SK#3O$5YK^FV%T PEAMO+$LHAW5^<7_!77X4^.
M?^":?[??P9_X*I_L_P"DS)X)\?>+;;1_C?X>TU7@TZ[\67-JUIXGTW4UC AB
ML_BUX.AO)$FD<%?&&C2WZ^5<SQRM_1_X _:?_8?\(^#M \)_#3XV? +P_P"!
MO#&GP:%X;T'PIXN\*6'A_1M.TY1##IVFV5A=1VEM#;@8,<2 [RSR;I'9CR'Q
MW^(W_!/_ /:8^%WB;X,?&_XH_!/QY\-_%T5I'KGAW4/'^FVBS2:?>P:C87=I
MJ&F:M9:GIM_8WMM!<6M]IUY:W<+H0DH1Y$;GEG.3PDXSS;*HRBW&499EE\91
M:W4HRQRDFNJ:379&BXLX4:37%'#335TUQ#D337=-9RTUYIM'\SO[:WQZN_\
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MGE.+DTFU%2;:3:5DVOQD_P""3G_!7;]F>[_9J\ ?L[?M+_$+0?V>?V@/V?\
M0[/X5^)O#GQ4G7P99^(+?PBC:1INJ:->ZJMM9PW\-A:P66N^'[V:WU73M2MI
MY1!/93P7!_5L_P#!1?\ 8- )/[7O[/8 !))^*7A3  Y)/_$R[5\@?M)_L]_\
M$9_VM?$\GCCXXI^SMXC\<7"HM]XRT?XA1^#O$FJB, 1G6]2\):_HSZ[(B 1Q
MSZRM]<11CRXI40!:^86_X)?_ /! %E93:?"HA@5(_P"&@_%O((P?^9V]*]__
M %5XH_Z)GB/_ ,,&=_\ SH.;_7[@/_HN>"__ !+^%O\ Z(S^A70-?T7Q5H>C
M^)O#>JV.N>'O$&F66LZ'K6EW,5YINK:3J5M'>:?J-A=PL\-S9WEK-%<6T\3-
M'+#(CHQ5@:*XCX+6GPSTWX3_  ^T7X-:AI6I_"OPYX6TKPMX#N]$U4ZYI?\
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MKXJ?^$QX-_\ C5'_ !#J?!+_ *.*^*G_ (3'@W_XU7<?M*_LI?&O]JO]M/\
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M<3M^V%?>)_!^J:_9>*?&5WX?\):EIFD> +[PMX:UM8M=\):@UHS//(X_7O\
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M** %P,YP,XQG'./3/7%  48  ')P  ,DDDX'J22?4DFBB@  "@*H"J
-!T  X '8"BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>abvc-20240208.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.21a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: /qpZs7xRiXgen8uBYXYsWaOIyaPtyJ1xqYkxuG98fdmqfyoiZ7/Djy4vm7Hmcf8M -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:ABVC="http://abvcpharma.com/20240208" elementFormDefault="qualified" targetNamespace="http://abvcpharma.com/20240208">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://abvcpharma.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="abvc-20240208_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="abvc-20240208_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>abvc-20240208_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.21a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>abvc-20240208_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.21a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://abvcpharma.com/role/Cover" xlink:href="abvc-20240208.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://abvcpharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140685806147280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Feb. 08, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb.  08,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ABVC BIOPHARMA, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001173313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-0014658<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">44370 Old Warm Springs Blvd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Fremont<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94538<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">668-0881<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABVC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MIR1-\SR. !9GD*88 J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%
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M)508H'Q3F:B\]E-L.>F.7F=Z_S!YU!Y:YU;*O8=7LN48<?R>Y0]02P,$%
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MO-9.&G_FB^$_7G\!4$L! A0#%     @ UTM(6 =!36*!    L0   !
M         ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #72TA8
ME!1K ^X    K @  $0              @ &O    9&]C4')O<',O8V]R92YX
M;6Q02P$"% ,4    " #72TA8F5R<(Q &  "<)P  $P              @ ',
M 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( -=+2%A(N!O/4@0
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M2P$"% ,4    " #72TA8)!Z;HJT   #X 0  &@              @ &Z$0
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #72TA899!Y
MDAD!  #/ P  $P              @ &?$@  6T-O;G1E;G1?5'EP97-=+GAM
7;%!+!08     "0 ) #X"  #I$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="ea193134-8k_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abvcpharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>abvc-20240208.xsd</File>
    <File>abvc-20240208_lab.xml</File>
    <File>abvc-20240208_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ea193134-8k_abvcbio.htm">ea193134-8k_abvcbio.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea193134-8k_abvcbio.htm": {
   "nsprefix": "ABVC",
   "nsuri": "http://abvcpharma.com/20240208",
   "dts": {
    "schema": {
     "local": [
      "abvc-20240208.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "abvc-20240208_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "abvc-20240208_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "ea193134-8k_abvcbio.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "report": {
    "R1": {
     "role": "http://abvcpharma.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2024-02-08",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea193134-8k_abvcbio.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-02-08",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea193134-8k_abvcbio.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Extension",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001213900-24-011360-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-24-011360-xbrl.zip
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MO2I?\>G@'NU]&<_L[CY?T7A<Y5^X+/Q6XA3QNT?EM]KZ([OQ?U!+ P04
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M]T:_328=!VO,KLO$_2)1GM#:FO2=8.OPL(EY%^Q:W()&S68\H,+!_@/I\5F
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MZ #?&. GI43=;5QGRF<EW6<*+T@IY$*(G#EP3$R8*)FWR,@2[31VVT9A:E)
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M]6U3T&39C>$FT90]X\_9"M\V&"2"^VN&7:.Y7ZS[)@K)]&8[:30KP>Z>>'O
MGLWHS9: /)MD:A:G(+6'+RR\X3*@^FD6\7%O!#S5'5C",!X-4^$<_1[?R!N*
M4:Q/KO'??,T.4*IG/@U<:DH!R=RK]@H>45^';"IZZP_N-]&:;%J!O,WZOFCR
M@R6B#]B9FW0[<]W.W#>I:>QC3<-2M'FU0:EU]]125>QC;>-JI<#U2IB6!SEG
MOD-%J,8XPS<<Q\"F>8)\FY@V>7?KAY<J<*Q$5$;L$KWF%(J=?U25I9XI?*M$
M24%9&1<K4K9&4-826X(7=#$VQ/9M6W\6V-J)/3C9*ZY+S:2=8AM3[ 2W1M$X
M!]5TEG)P@2^>3E0D/3:7P48#MKHG,T8%:AX*%D":&N3%?'R"@Z\QO4CQH2-L
MWL5VWC1R;:$9 &R?U=="P'>I[._@+R9<PN3< +OO]Y"F?,N;>BSRVMC:T?O:
MV?%TT]OYV_?^QK=@NM-^[X,Q/&0?N5ZN<.?@ FPT&+"+Y?#L\6RRL7NZDB:
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MFEW B5:+/%N&K*6D)2MAW]1\G0-5IZ\'ANF?PDYF\X#E &V'T8VA9US@7W"
MFW!I<!CP>98"?XB3A/9FM[>SLX/_;=(TINLD>?WW;F<!_UZK510;UI-NP6Z
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MEE8LS)AG:Q(.YME5:DURJ<8F8$\O,M.@F35O-J[=@@X,"IWR!$[-.:_(>K7
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M.-L/>[PD1M8-X-,F^9PI%)*^RJ3@_#J#!JN&UMCA X<W;TTK!P@OY09,!<?
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M]G]')BVI(0+?#;)A><8G1LDBN88$G+G<#,R>EW?F>7>QM[6-H[2"GW4AD<B
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M>%! 2ANT5Z/#&4I@6C&B_-5%ILBWHRDZY/8P@9XAW]:))$"Y>@[C"IS[3?Q
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M%)5E-+L0$ J3XJR3:XD.<DS:: XR'=8JD&/!/<A3?5WGN"9O'ZG>LMS,,1G
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M'W[:.SGX2&Y0AY/W1V__/U!+ P04    " #72TA8!CB-"V .   X,P  &@
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MG ?JCH3R72SRL:338Z\ >2Z[W^&<_>U;D/1MS>NJ9[<XWBTE\\+7SQ^\\:8
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MWXIR-K3;I=]\";\*0[\Q\Q]02P$"% ,4    " #72TA8,K,]BRP#  #I"P
M$0              @ $     86)V8RTR,#(T,#(P."YX<V102P$"% ,4
M" #72TA8_1P"^_T*  " A@  %0              @ %; P  86)V8RTR,#(T
M,#(P.%]L86(N>&UL4$L! A0#%     @ UTM(6&TCB/Y8!P  V5<  !4
M         ( !BPX  &%B=F,M,C R-# R,#A?<')E+GAM;%!+ 0(4 Q0    (
M -=+2%CM3&__114  +1Z   7              "  186  !E83$Y,S$S-"TX
M:U]A8G9C8FEO+FAT;5!+ 0(4 Q0    ( -=+2%AQ7%5XJ X  $IM   :
M          "  9 K  !E83$Y,S$S-&5X,3 M,5]A8G9C8FEO+FAT;5!+ 0(4
M Q0    ( -=+2%AY*",H+SL  +XG 0 9              "  7 Z  !E83$Y
M,S$S-&5X-"TQ7V%B=F-B:6\N:'1M4$L! A0#%     @ UTM(6 8XC0M@#@
M.#,  !H              ( !UG4  &5A,3DS,3,T97@Y.2TQ7V%B=F-B:6\N
9:'1M4$L%!@     '  < X0$  &Z$      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>ea193134-8k_abvcbio_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="abvc-20240208.xsd" xlink:type="simple"/>
    <context id="AsOf2024-02-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2024-02-08</startDate>
            <endDate>2024-02-08</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2024-02-08" id="ixv-296">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2024-02-08" id="ixv-297">0001173313</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2024-02-08" id="ixv-317">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2024-02-08" id="ixv-318">2024-02-08</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2024-02-08" id="ixv-319">ABVC BIOPHARMA, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2024-02-08" id="ixv-320">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2024-02-08" id="ixv-321">001-40700</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2024-02-08" id="ixv-322">26-0014658</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2024-02-08" id="ixv-323">44370 Old Warm Springs Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="AsOf2024-02-08" id="ixv-324">Fremont</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2024-02-08" id="ixv-325">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2024-02-08" id="ixv-326">94538</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2024-02-08" id="ixv-327">510</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2024-02-08" id="ixv-328">668-0881</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2024-02-08" id="ixv-329">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2024-02-08" id="ixv-330">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2024-02-08" id="ixv-331">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2024-02-08" id="ixv-332">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2024-02-08" id="ixv-333">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2024-02-08" id="ixv-334">ABVC</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2024-02-08" id="ixv-335">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2024-02-08" id="ixv-336">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
